Literature DB >> 27917390

Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases.

Yiming Zhong1, Amy J Johnson1, John C Byrd1, Jason A Dubovsky1.   

Abstract

IL2-inducible T-cell kinase (ITK), a member of the Tec family tyrosine kinases, is the predominant Tec kinase in T cells and natural killer (NK) cells mediating T cell receptor (TCR) and Fc receptor (Fc R) initiated signal transduction. ITK deficiency results in impaired T and NK cell functions, leading to various disorders including malignancies, inflammation, and autoimmune diseases. In this mini-review, the role of ITK in T cell signaling and the development of small molecule inhibitors of ITK for the treatment of T-cell related disorders is examined.

Entities:  

Keywords:  IL2-inducible T-cell kinase (ITK); T cell signaling; inhibitors of ITK

Year:  2014        PMID： 27917390      PMCID： PMC5134889          DOI： 10.14304/surya.jpr.v2n6.1

Source DB:  PubMed          Journal:  Postdoc J        ISSN： 2328-9791


  94 in total

1.  Mutation of Tec family kinases alters T helper cell differentiation.

Authors:  E M Schaeffer; G S Yap; C M Lewis; M J Czar; D W McVicar; A W Cheever; A Sher; P L Schwartzberg
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

2.  Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton.

Authors:  Derek Dombroski; Richard A Houghtling; Christine M Labno; Patricia Precht; Aya Takesono; Natasha J Caplen; Daniel D Billadeau; Ronald L Wange; Janis K Burkhardt; Pamela L Schwartzberg
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

3.  Antiviral immune responses in Itk-deficient mice.

Authors:  M F Bachmann; D R Littman; X C Liao
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways.

Authors:  W-L Zhao
Journal:  Leukemia       Date:  2009-10-29       Impact factor: 11.528

5.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Authors:  Jennifer A Woyach; Kelly Smucker; Lisa L Smith; Arletta Lozanski; Yiming Zhong; Amy S Ruppert; David Lucas; Katie Williams; Weiqiang Zhao; Laura Rassenti; Emanuela Ghia; Thomas J Kipps; Rose Mantel; Jeffrey Jones; Joseph Flynn; Kami Maddocks; Susan O'Brien; Richard R Furman; Danelle F James; Fong Clow; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

6.  Optimisation of ITK inhibitors through successive iterative design cycles.

Authors:  Matthias Herdemann; Alexander Weber; Jérôme Jonveaux; Frank Schwoebel; Michael Stoeck; Isabelle Heit
Journal:  Bioorg Med Chem Lett       Date:  2011-01-14       Impact factor: 2.823

7.  Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases.

Authors:  Beston F Nore; Pekka T Mattsson; Per Antonsson; Carl-Magnus Bäckesjö; Anna Westlund; Johan Lennartsson; Henrik Hansson; Peter Löw; Lars Rönnstrand; C I Edvard Smith
Journal:  Biochim Biophys Acta       Date:  2003-02-21

8.  Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome.

Authors:  Jessica Shin; Stefano Monti; Daniel J Aires; Madeleine Duvic; Todd Golub; David A Jones; Thomas S Kupper
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk.

Authors:  W Ellmeier; S Jung; M J Sunshine; F Hatam; Y Xu; D Baltimore; H Mano; D R Littman
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307
View more
  5 in total

1.  Propofol Alters Long Non-Coding RNA Profiles in the Neonatal Mouse Hippocampus: Implication of Novel Mechanisms in Anesthetic-Induced Developmental Neurotoxicity.

Authors:  Sarah Logan; Congshan Jiang; Yasheng Yan; Yasuyoshi Inagaki; Thiago Arzua; Xiaowen Bai
Journal:  Cell Physiol Biochem       Date:  2018-09-27

Review 2.  Hallmarks of Cancers: Primary Antibody Deficiency Versus Other Inborn Errors of Immunity.

Authors:  Hassan Abolhassani; Yating Wang; Lennart Hammarström; Qiang Pan-Hammarström
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561

3.  MicroRNA-155 acts as an anti-inflammatory factor in orbital fibroblasts from Graves' orbitopathy by repressing interleukin-2-inducible T-cell kinase.

Authors:  Yeon Jeong Choi; Charm Kim; Eun Woo Choi; Seung Hun Lee; Min Kyung Chae; Hyung Oh Jun; Bo-Yeon Kim; Jin Sook Yoon; Sun Young Jang
Journal:  PLoS One       Date:  2022-08-18       Impact factor: 3.752

Review 4.  Combination Approaches to Target PD-1 Signaling in Cancer.

Authors:  Emily K Moore; Marianne Strazza; Adam Mor
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

5.  Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.

Authors:  Sami Mamand; Rebecca L Allchin; Matthew J Ahearne; Simon D Wagner
Journal:  Sci Rep       Date:  2018-09-21       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.